微信直播

AME新书《肺癌靶向治疗:聚焦阿法替尼》译者招募

Published at: 2015年第1卷第S1期

关键词:

分子靶向治疗是指针对肿瘤发生、发展过程中的关键大分子,通过特异性阻断肿瘤细胞的信号传导,来控制其基因表达和改变生物学行为,或是通过阻止肿瘤血管生成,从而抑制肿瘤细胞的生长和繁殖,发挥抗肿瘤作用。分子靶向治疗与传统的化疗相比,存在巨大的优势——让个体化治疗成为可能;靶点专一、毒副反应轻;治疗方法简便易行;改善晚期患者生活质量;分子靶向药物与化疗联合使用能提高疗效。

2017年2月获得CFDA颁发的进口药品注册证的阿法替尼是中国首次批准的二代肺癌靶向药物,其在中国上市对于中国肺癌患者具有重要意义,为了帮助学术研究者、临床工作者、患者了解该药物的利弊、用法和临床效果,AME出版社邀请了广东省人民医院的吴一龙教授、西班牙Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital的Rafael Rosell教授和美国UCSF Helen Diller Family Comprehensive Cancer Center的Trever G. Bivona教授共同担任主编出版英文专著Targeted Therapy for Lung Cancer: Afatinib Focused .

本书荟萃了全世界关于阿法替尼的最新研究进展、研究数据与评述,为临床工作者使用该药提供了科学、严谨、全面的评估工具。AME将同步出版本书的中文版《肺癌靶向治疗:聚焦阿法替尼》,现诚邀国内外该领域优秀医学工作者参与本书的翻译工作!

此专题待翻译文章目录如下,欢迎各位认领:

1

Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients

2

EGFR, EGFR TKI, and EMSI: a never-ending story

3

Advances on EGFR mutation for lung cancer

4

Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements

5

HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches

6

Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer

7

Irreversible EGFR-TKIs: dreaming perfection

8

Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations

9

EGFR inhibition and more: a new generation growing up

10

Update on third-generation EGFR tyrosine kinase inhibitors

11

The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung

12

Treatment of advanced squamous cell carcinoma of the lung: a review

13

Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future

14

A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting

15

Keeping our fingers crossed on 2 generation EGFR TKIs: is better good enough?

16

Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC—are we making progress?

17

Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?

18

Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?

19

Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer?

20

Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer—the Holy Grail in cancer treatment?

21

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future

22

Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives

23

Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy

24

Metastatic lung cancer in the age of targeted therapy: improving long-term survival

25

Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?

26

Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?

27

Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?

28

Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials

29

Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?

30

Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

31

Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study

32

Afatinib and gefitinib: a direct comparison

33

Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy—would patients agree?

34

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

35

Treating acquired resistance to EGFR-tyrosine kinase inhibitors: Still a work in progress

36

Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors

37

Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance

38

EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance

39

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

40

Precision medicine in lung cancer: the battle continues

认领方法:

  1. 下载译者报名表(http://rlxt.amegroups.cn/#notices/9),填写完毕后发送到:rlxt@amegroups.com

  2. 编辑部会综合选择最匹配的专家参与翻译,并给符合要求的专家注册系统账号和获取稿件等信息;

  3. 每位会员/译者认领的书籍和文章均不得超过3本/3篇,编辑部将会对超出译者做出适当的调整;

  4. 注:凡是通过编辑部审核并注册系统账号的专家,我们将会在系统委员风采上展示您的个人风采(包括姓名,科室和简介)

  • 认领截止日期:本次认领长期有效,直至认领完毕。

  • 认领成功后,请在认领成功后的三周内将翻译稿及个人简介上传到系统;并发送到rlxt@amegroups.com

凡翻译质量通过审核的译者,可获得:

  1. 每翻译一篇文章,即可获得价值200元人民币的科研时间积分(200快币),可换购各种图书/杂志,免费登录视频数据库ASVIDE,观看手术视频(积分限免)。

  2. 译者署名权。

  3. 中文版出版后,获赠新书一本。

主编风采:

吴一龙

肿瘤学教授,博士生导师,美国外科学院院士,曾任广东省医学科学院(GAMS)、广东省人民医院(GGH)副院长,广东省肺癌研究所(GLCI)所长;现任中国抗癌协会(CACA)常务理事、临床肿瘤协作中心(CSCO)候任主任委员、肺癌专业委员会(CSLC)第三届委员会主任委员、广东省临床试验协会(GACT)会长、世界华人胸外科学会(ICSTS)会长。中央、省、市保健委员会专家组成员、国际肺癌研究会(IASCL)国际分期委员会委员、美国临床肿瘤协会(ASCO)国际事务部委员,国内外多家中英文杂志主编、副主编、编委。为国务院特殊津贴享受者。

Rafael Rosell,MD, PhD

Director, Cancer Biology & Precision Medicine Program

Catalan Institute of Oncology Germans Trias i Pujol Health Sciences Institute and Hospital Badalona, Barcelona, Spain.

Dr. Rafael Rosell is Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona, Barcelona, Spain), Chief Scientific Officer, Chairman and Founder of Pangaea Biotech SL (Barcelona), Chief Medical Officer and President of the Dr Rosell Oncology Institute, Quirón Dexeus University Hospital (Barcelona) and Founder and President of the Molecular Oncology Research Foundation (Barcelona). He is Founder and Director of International Relations and Projects, Spanish Lung Cancer Group (SLCG) and a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP).

Trever G. Bivona, MD, PhD

Professional Experience

  • 1998-2005
    MD-PhD, Medical Scientist Training Program, NYU School of Medicine

  • 2005-2007
    Resident House Staff, Internal Medicine, Brigham and Women’s Hospital

  • 2007-2011
    Medical Oncology Fellow, Memorial Sloan-Kettering Cancer Center

  • 2008-2011
    Research Fellow, Laboratory of Charles Sawyers, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center

  • 2011-2015
    Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco

  • 2011- present
    Member, UCSF Helen Diller Comprehensive Cancer Center

  • 2011- present
    Faculty Member, California Institute for Quantitative Biosciences (QB3)

  • 2015-present
    Associate Professor, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco

AME科研时间系列图书

AME推出的本系列图书,将临床、科研、人文三者有机结合到一起,像西餐一样,烹调出丰富的味道,搭配出一道精美的佳肴呈现给各位。

comments powered by Disqus

附件